Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
Avantor Inc(AVTR)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for AVTR
10/19/2026: AVTR (3-star) is a STRONG-BUY. BUY for 99 days. Simulated Profits (78.62%). Updated daily EoD!
Avantor Inc is a global provider of critical products and services to the life sciences and advanced technology industries. It has a leading position in laboratory distribution and bioprocessing materials, largely driven by the transformational acquisition of VWR. The company's main strength lies in its deep integration into customer workflows, which creates recurring revenue. The primary growth story centers on increasing biopharma innovation and bioprocessing needs. However, investors must consider risks including high debt levels, industry cyclicality in research spending, and intense competition from larger rivals. The stock is typically better suited for growth-oriented investors rather than those seeking dividends, and developments in R&D spending should be closely monitored.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Strong fit | The company operates in the growing life sciences sector with exposure to biopharma R&D trends. |
| Momentum investor | Mixed fit | Momentum depends on the current trend in biopharma spending and market sentiment regarding inventory levels. |
| Value investor | Mixed fit | Valuation is often tied to market multiples for life science tools and the company's ability to deleverage. |
| Dividend investor | Weak fit | Avantor does not pay a dividend, making it unsuitable for income-focused portfolios. |
| Low-risk investor | Weak fit | The company's leverage and sensitivity to industry cycles contribute to moderate stock price volatility. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | Medium / high | The stock price reacts to changes in biopharma R&D spending and broader market sentiment. |
| Valuation risk | Medium | Equity valuation is sensitive to earnings growth expectations in the life science tools market. |
| Competition risk (Life Science Tools) | High | Large incumbents like Thermo Fisher possess greater scale and R&D budgets. |
| Business quality | Medium / high | The company provides essential, recurring products to the drug development industry. |
| Dividend income | Low / none | No dividend is paid, precluding income generation. |
| Execution risk | Medium | Successfully integrating past acquisitions while deleveraging remains a key operational priority. |
Price Behavior
Strong Uptrend
The stock has maintained a strong upward price trend across the last three quarters.
Choppy
The stock has experienced frequent reversals and pronounced short-term price swings.
Analysis of Past Performance
Type Stock | Historic Profit 12.85% | Avg. Invested days 38 | Today’s Advisory Strong Buy |
Upturn Advisory Rating  | Upturn Advisory Performance  3.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 10/19/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 11.11B USD | Price to earnings Ratio - | 1Y Target Price 15.46 |
Price to earnings Ratio - | 1Y Target Price 15.46 | ||
Volume (30-day avg) 9.2M shares | Beta 0.94 | 52 Weeks Range 7.26 - 16.55 | Updated Date 10/18/2026 |
52 Weeks Range 7.26 - 16.55 | Updated Date 10/18/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.84 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Laboratory Solutions | Consumables, chemicals, and equipment provided through the VWR channel. | This is the 'day-to-day' sales business that provides recurring revenue from labs. |
| Biopharma Production | High-purity raw materials and single-use systems used to manufacture biologics. | This is the 'growth engine' linked to the success of new drug launches. |
| Geography | Operations spanning North America, Europe, and AMEA regions. | Global reach allows for stability, though exposes the firm to currency fluctuations. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Valuation
Trailing PE - | Forward PE 16.86 | Enterprise Value 13.37B | Price to Sales(TTM) 1.69 |
Enterprise Value 13.37B | Price to Sales(TTM) 1.69 | ||
Enterprise Value to Revenue 2.04 | Enterprise Value to EBITDA 118.46 | Shares Outstanding 676.36M | Shares Floating 657.81M |
Shares Outstanding 676.36M | Shares Floating 657.81M | ||
Percent Insiders 1.53 | Percent Institutions 105.68 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.